Tissue distribution of surface-modified, drug-loaded PLGA nanoparticles via direct and systemic administration
J. Lu, C.C. Weller, M.F. Rauch, E.C. Ferreira, J. Park, W.M. Saltzman, M.S. Cartiera
Carigent Therapeutics, Inc., US
Keywords: tissue distribution, surface-modified, PLGA
Abstract:A polymeric nanoparticle platform for delivery of chemotherapeutics and RNAi materials could be a useful tool in treating cancer and other devastating diseases as it provides protection of contents from the in vivo environment, increased circulation time, sustained release, and increased efficacy. Investigation of the biodistribution of NPs loaded with drugs and other small molecules is important for progress in this area as it provides an understanding of where nanoparticles travel, informs design of formulations and dosing strategies, allows interpretation of in vitro/in vivo efficacy, and reveals potential target organs. The Carigent platform distinguishes itself from other PLGA delivery systems in that incorporates a robust and versatile surface-modification technique, which allows a high density of ligands to be attached to the particle surface and high loading of small molecules, proteins, and RNAi materia. Our particle characterization and preliminary in vivo distribution data from administering several types of Carigent particles via various routes suggests the versatility and advantages of our platform over other systems.